Dr Lal Pathlabs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹874 Cr +19.6% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
DL

Dr Lal Pathlabs Ltd

Q3 FY26Healthcare Services

Dr Lal Pathlabs Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹660Cr
+10.6% YoY
−9.7% QoQ
Net profit
₹91Cr
−7.1% YoY
−40.1% QoQ
Margin
27%
+1 pp YoY
−4 pp QoQ
Price₹1,894
Market cap₹31.6K Cr
P/E56.3

The short version

The company targets organic revenue growth of 11%-12% for the current financial year, aiming to improve this baseline going forward. The company aims for organic revenue growth of 11%-12% for the current financial year, with aspirations to improve beyond this baseline in the medium term.

From Dr Lal Pathlabs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets organic revenue growth of 11%-12% for the current financial year, aiming to improve this baseline going forward.
  • Patient volume growth has shown a steady increase from a low base, with expectations of slow and steady improvement rather than sudden jumps.
  • Expansion in newer markets including Tier 2, Tier 3, and rural towns will drive volume growth by increasing geographic spread and patient access.
  • The Swasthfit preventive health testing model is scaling well into smaller towns, contributing to incremental volumes without cannibalizing margins.
  • Inorganic growth opportunities are being pursued selectively, particularly larger acquisitions in South markets and standalone labs in smaller regions, adding to volume and revenue.

2 more points from Dr Lal Pathlabs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Dr Lal Pathlabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • For FY26, capex is estimated around Rs. 150-160 crore, higher than the usual Rs. 50-70 crore, due to investments in radiology centers and the new Sovaaka preventive wellness program.
  • Radiology centers require significant investment; one center costs about Rs. 15-16 crore. Plans include opening 1 or 2 more advanced radiology centers.
  • The typical sustainable capex going forward may settle around Rs. 60-70 crore operational capex plus about Rs. 30-40 crore for 2 radiology centers, totaling approximately Rs. 100-110 crore annually.
  • Additional investments may arise from new initiatives or expansions beyond current plans.

2 more points from Dr Lal Pathlabs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Dr Lal Pathlabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript from Dr. The discussion primarily focuses on operational performance, growth strategies, margin outlook, scaling models, new initiatives like Sovaaka, and market expansion plans.

Dr Lal Pathlabs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Dr Lal Pathlabs Ltd Q3 FY26 results — key figures

Dr Lal Pathlabs Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue660597+10.6%731-9.7%
Operating profit (EBITDA)179154+16.2%224-20.1%
Operating margin27%26%+1 pp31%-4 pp
Profit before tax124138-10.1%204-39.2%
Net profit (PAT)9198-7.1%152-40.1%
EPS (₹)5.405.78-6.6%8.99-39.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹874 Cr, net profit ₹194 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q3 FY26)

    FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —

  • Aster DM Quality (Q3 FY26)

    Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…

  • Chandan Healthca (Q3 FY26)

    The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…

  • Rainbow Childrens Medicare (Q3 FY26)

    Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dr Lal Pathlabs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dr Lal Pathlabs Ltd Q3 FY26 results?

The company targets organic revenue growth of 11%-12% for the current financial year, aiming to improve this baseline going forward. The company aims for organic revenue growth of 11%-12% for the current financial year, with aspirations to improve beyond this baseline in the medium term.

What is Dr Lal Pathlabs Ltd share price analysis?

Dr Lal Pathlabs Ltd currently shows a neutral. The stock trades at a P/E of 56.3 with a market cap of ₹31,635 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dr Lal Pathlabs Ltd planning capital expenditure?

For FY26, capex is estimated around Rs. 150-160 crore, higher than the usual Rs. 50-70 crore, due to investments in radiology centers and the new Sovaaka preventive wellness program.

Keep Dr Lal Pathlabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.